Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) generates a diverse stream of news centered on oncology, rare pediatric cancers, RNA-based therapeutics, AI-driven discovery, and nanomedicine. As a clinical-stage biopharmaceutical company, it regularly reports on scientific publications, joint venture progress, platform launches, and financing developments that shape its pipeline and corporate strategy.
Investors and researchers following OTLC news will encounter updates on key assets such as OT-101, a TGFB2 antisense agent associated with rare pediatric designation for DIPG through joint venture GMP Bio, and Sapu003, an intravenous Deciparticle formulation of everolimus developed by 45% owned JV Sapu Nano. Press releases highlight biomarker frameworks for identifying tumors likely to respond to Sapu003, pharmacokinetic data showing reduced gastrointestinal accumulation compared with oral everolimus, and broader Deciparticle platform data demonstrating formulation of multiple hydrophobic drug classes.
Oncotelic’s news flow also covers its PDAOAI evidence-interrogation platform, including open access for researchers to a TGF-β knowledge corpus of more than 125,000 PubMed abstracts via a dedicated Discord channel. Additional announcements describe peer-reviewed publications on context-dependent biomarkers in liver and pancreatic cancer, sub-15 nm nanoparticles for drug delivery, and survival-associated biological axes such as TGFB2, DNMT3A, and GMPS.
From a corporate and capital markets perspective, OTLC news includes independent valuations of its joint venture GMP Bio pipeline, potential fair-value remeasurements under U.S. GAAP, and registration statements related to equity purchase and note agreements with institutional investors. Regularly reviewing this news page allows readers to track how scientific advances, joint venture activities, AI platforms, and financing structures intersect within Oncotelic’s evolving oncology and rare disease portfolio.
Oncotelic Therapeutics (OTLC) has made significant progress towards its IPO, enhancing its OT-101 immunotherapy program with plans for at least 10 investigator-initiated studies (IIS) in 2023. The company is actively developing its manufacturing capabilities and expanding into animal health through its subsidiary, Pet2DAO. Clinical trials for OT-101 in pancreatic and glioma cancers are advancing, showcasing promising results, such as a 55% long-term disease control rate in pancreatic cancer patients. Additionally, the company has successfully reduced R&D costs by over 95% while maintaining project expansion.
Oncotelic Therapeutics (OTLC) presented compelling evidence at the 12th AACR-JCA Joint Conference, confirming TGF-β2 as a crucial target for gliomas. Their retrospective analysis showed that high TGF-β2 levels correlate with decreased overall survival (OS). Notably, patients with reduced TGF-β2 levels experienced a dramatic OS increase: from 9 to 22 months in pediatric brainstem patients and from 25 to 94 months in glioma patients treated with TMZ or radiation (p<0.0001). This data reaffirms Oncotelic's commitment to developing therapies targeting TGF-β2, particularly after the failure of bintrafusp alfa.
Oncotelic Therapeutics (OTLC) recently shared presentation materials from the Society for Neuro-Oncology’s 27th Annual Meeting held from November 16-20, 2022. Notable abstracts included studies on OT-101, an antisense therapy targeting TGF-β2 for glioblastoma and pediatric diffuse intrinsic pontine glioma (DIPG). The company is advancing a Phase 1 study protocol for OT-101 in pediatric DMG, emphasizing the urgent need for new treatments in this area. The participation in the SNO meeting underscored the clinical promise of OT-101 and garnered interest from key opinion leaders in the field.
Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced the release of presentation materials from the SITC 37th annual meeting held in Boston, discussing their OT-101 anti-TGF-β immunotherapy. Key stakeholders and opinion leaders were engaged, with plans for upcoming clinical studies emphasizing its efficacy against pancreatic cancer. OT-101 has completed multiple clinical trials, including those for COVID-19 and pediatric brain cancer (DIPG). The company is focused on improving treatment outcomes for rare diseases, including Parkinson's Disease and Erectile Dysfunction.
Oncotelic Therapeutics (OTLC) announced the submission of a Phase 1 clinical study protocol to the FDA for OT-101, a TGF-β2 inhibitor, aimed at treating pediatric patients with diffuse midline glioma (DMG). This open-label trial, G101, will assess the safety and tolerability of administering OT-101 via intraventricular injection. DMG is a highly aggressive brain tumor with a poor prognosis. OT-101 has previously shown activity in relapsed cancer cases and received orphan designation, indicating its potential to address unmet medical needs in pediatric oncology.
Oncotelic Therapeutics, Inc. (OTLC) announced a contract approval with BARDA for the development of OT-101, targeting long-term COVID-19 respiratory distress effects. The project encompasses collecting clinical data from COVID-19 patients in Peru and Argentina to support future trials. OT-101, which has completed seven clinical trials, aims to address various indications including COVID-19 and DIPG. The project is fully funded by federal sources, enhancing the potential for advancing therapeutic options in the post-COVID landscape.
Oncotelic Therapeutics (OTLC) has officially launched an animal health division, emphasizing its commitment to innovative drug development for animals, particularly pets. The initiative aims to utilize blockchain technology and a decentralized autonomous organization (DAO) to improve drug development processes. Chairman and CEO Dr. Vuong Trieu expressed optimism about the integration of DAOs within the animal health sector and the potential for existing drug candidates to succeed in this new market. The company acknowledges the inherent risks in its forward-looking statements related to future product development and regulatory approvals.
Oncotelic Therapeutics (OTCQB:OTLC) announced its presentation at the SITC 37th Annual Meeting, scheduled for November 10-12, 2022, in Boston, MA. The presentation, titled Mechanism of Action for OT-101 TGF-ß immunotherapy, focuses on the ongoing development of OT-101 for pancreatic cancer treatment. CEO Dr. Vuong Trieu highlighted that pancreatic cancer has a low survival rate, urging the need for innovative therapies. The P001 trial showed 54% disease control in evaluable patients, indicating promising results for OT-101 against this aggressive cancer.
Oncotelic Therapeutics (OTCQB:OTLC) has announced two poster presentations at the 2022 Society for Neuro-Oncology Annual Meeting scheduled for November 16-20, 2022, in Tampa Bay, Florida. The presentations will focus on OT-101, a treatment for glioblastoma and DIPG, emphasizing its potential after radiation therapy. Dr. Vuong Trieu, CEO, highlighted the urgent need for innovative treatments for DIPG, a fatal pediatric brain cancer. Oncotelic aims to accelerate OT-101's clinical development following the formation of a joint venture with Sapu Bioscience.
Oncotelic Therapeutics (OTLC) reported a net profit of $17 million for Q2 2022, driven by a fair value of $22.6 million for its joint venture (JV) with Dragon Overseas and GMP Biotechnology. Noteworthy highlights include a significant reduction in expenses by over $3.5 million compared to Q2 2021 and a strategic plan for OT-101's further development, targeting pediatric cancers. The JV is positioned for an IPO, and Oncotelic anticipates lower R&D and G&A expenses moving forward.